ALL is the most common form of cancer in children and arises predominantly (80-85% of cases) from the transformation of B cell progenitors 1 . Current therapies have improved the 5-year eventfree survival of children with ALL to 80-90%. However, despite such advances, ALL remains a leading cause of cancer-related death in children and young adults. Moreover, the outcome for adults with ALL tends to be much worse, as only 30% of adults achieve long-term disease-free survival 2 . Most current therapies are nonspecific and cause off-target effects such as impaired intellectual and psychomotor function, neuroendocrine abnormalities, impaired reproductive capacity, cardiotoxicity and secondary neoplasms [3] [4] [5] . Moreover, some patients who currently receive intensive therapy are probably being over-treated and could potentially be cured by less-intensive regimens 6 . Therefore, new stratification methods and therapies need to be developed to more accurately identify and treat high-risk groups of B-ALL.
ALL is the most common form of cancer in children and arises predominantly (80-85% of cases) from the transformation of B cell progenitors 1 . Current therapies have improved the 5-year eventfree survival of children with ALL to 80-90%. However, despite such advances, ALL remains a leading cause of cancer-related death in children and young adults. Moreover, the outcome for adults with ALL tends to be much worse, as only 30% of adults achieve long-term disease-free survival 2 . Most current therapies are nonspecific and cause off-target effects such as impaired intellectual and psychomotor function, neuroendocrine abnormalities, impaired reproductive capacity, cardiotoxicity and secondary neoplasms [3] [4] [5] . Moreover, some patients who currently receive intensive therapy are probably being over-treated and could potentially be cured by less-intensive regimens 6 . Therefore, new stratification methods and therapies need to be developed to more accurately identify and treat high-risk groups of B-ALL.
The transcription factor STAT5 has a critical role in the transformation of progenitor B cells 7 . For example, STAT5 is required for the transformation of progenitor B cells dependent on the oncogenic tyrosine kinases BCR-ABL and TEL-JAK2 (refs. 8-10) . However, the exact mechanism by which STAT5 drives transformation has remained unclear. Published studies have suggested that STAT5 simply promotes the survival of progenitor B cells and that the role of STAT5 in transformation is limited to its pro-survival effects 11, 12 . However, other roles for STAT5 in B-ALL have not been explored.
Deregulation of signaling via the pre-BCR has also been shown to be important in the development of B-ALL. For example, defects in the adaptor BLNK, when paired with activated STAT5, promote pre-B cell transformation 13 . However, BLNK regulates many downstream pathways, and which of these pathways exert tumor-suppressor function remains unclear. Finally, in addition to the pre-BCR, various transcription factors, including PAX5, EBF1 and IKAROS, have been suggested to serve a key role in the transformation of progenitor B cells 14 . These transcription factors form a transcriptional network that has a key role in promoting B cell differentiation 15 . Notably, the genes encoding these transcription factors are frequently deleted in samples from patients with B-ALL, which suggests that they have a role in transformation 14 . Consistent with that observation, haploinsufficiency for Pax5 or Ebf1 acts in synergy with activation of STAT5 to initiate leukemia 16 . However, how these transcription factors suppress B-ALL, whether they interact with STAT5 and if that interaction is important in transformation remain unknown.
Here we found that STAT5 acted together with defects in a coherent pre-BCR pathway that included the adaptor BLNK, the associated kinases BTK and PKCβ and the downstream transcription factors NF-κB and IKAROS. Using microarray analysis and chromatin immunoprecipitation followed by deep sequencing (ChIP-Seq), we found that STAT5 tended to reciprocally regulate target-gene expression by the NF-κB and IKAROS tumor-suppressor pathways. Moreover, the binding of STAT5 overlapped that of a larger cohort of transcription factors at super-enhancers linked to genes encoding products that control the survival, proliferation and differentiation of progenitor B cells. Finally, analysis of samples from human patients with B-ALL revealed that the ratio of activation of STAT5 to the expression of IKZF1 or NF-κB was a more powerful predictor of disease outcome than was either of these factors alone. Thus, an imbalance between STAT5 and the pre-BCR-NF-κB-IKAROS pathway promotes the development of B-ALL, while the degree of imbalance underlies the severity of disease, as measured by overall survival and remission duration.
RESULTS

Stat5b-CA mice spontaneously develop B-ALL-like disease
To study the role of STAT5 in B-ALL, we used transgenic mice that express a constitutively active form of STAT5b throughout B cell development (Stat5b-CA mice) 17 . Approximately 2-10% of Stat5b-CA mice develop leukemia 13, 17 characterized as progenitor B cell leukemia on the basis of the expression pattern of the signal-transduction receptor CD19, the cytokine receptor subunit IL-7Rα, the pre-BCR and the cell-surface marker BP-1 ( Fig. 1a and Supplementary Fig. 1a) . The low incidence of leukemia suggested that the Stat5b-CA cells required additional mutations for the induction of transformation. To identify pathways commonly mutated in the Stat5b-CA leukemia, we carried out microarray analyses of pre-B cells sorted from C57BL/6 bone marrow and pre-B leukemic cells from Stat5b-CA mice. As expected, Stat5b-CA leukemic cells had higher expression of the known STAT5 targets Myc, Ccnd2 and Ccnd1 (which encode the cell-cycle regulators c-Myc, cyclin D2 and cyclin D1, respectively) than that of pre-B cells from C57BL/6 control mice (Fig. 1b) . Interestingly, the leukemic cells also had higher expression of the gene encoding asparagine synthetase (Asns) (Fig. 1b) , a major target of chemotherapy for ALL 18 . Many other genes were also deregulated in Stat5b-CA pre-B leukemia cells, including those encoding components of the pre-BCR signaling pathway, such as Blk, Syk and Prkcb (Fig. 1b) . In contrast, surface expression of the pre-BCR was increased (Fig. 1a,b) . That finding was consistent with published studies showing that signaling via the pre-BCR triggers a negative feedback loop that reduces the expression genes that encode components of the pre-BCR (λ5 (encoded by Igll1) and VpreB1 (encoded by Vpreb1) 19 . Together these results led us to hypothesize that activation of STAT5 works together with defects in components of pre-BCR signaling to initiate B-ALL.
STAT5b-CA and defects in pre-BCR pathway promote B-ALL To test our hypothesis, we bred Stat5b-CA mice to mice harboring loss-of-function mutations in the gene encoding the pre-BCR adaptor BLNK (Blnk) or in genes encoding the downstream kinases BTK (Btk; Xid mutant) or PKCβ (Prkcb). The resultant Stat5b-CA × Blnk +/− , Stat5b-CA × Xid and Stat5b-CA × Prkcb −/− mice rapidly developed leukemia with high frequency (Fig. 1c) . In contrast, Blnk +/− , Xid and Prkcb −/− control mice never developed leukemia, and Stat5b-CA mice had only a low incidence of leukemia (Fig. 1c) . The Stat5b-CA × Blnk +/− , Stat5b-CA × Xid and Stat5b-CA × Prkcb −/− leukemia resembled pre-B cell leukemia, with high expression of CD19, IL-7Rα, the pre-BCR and BP-1 but low or absent expression of the leukosialin CD43 and the immunoglobulin κ-chain and λ-chain (Fig. 1d and data not shown). Likewise, the global mRNA-expression patterns in Stat5b-CA × Blnk +/− , Stat5b-CA × Xid and Stat5b-CA × Prkcb −/− leukemia and in the control samples from sorted wild-type, Xid and Stat5b-CA pre-B cells used for comparison were most similar to that of large pre-B cells (Hardy fraction C') in the database of the Immunological Genome Project (http://www.immgen.org) (Supplementary Fig. 1a) . Thus, these results confirmed our hypothesis that activation of STAT5 worked together with defects in a specific pre-BCR signaling pathway to drive highly penetrant progenitor B cell leukemia.
Survival effects of STAT5 alone do not initiate leukemia Published studies have suggested that the role of STAT5 in the transformation of progenitor B cells is solely to prevent apoptosis 11, 12 . To test that possibility, we bred Blnk +/− mice with mice that have transgenic expression of Bcl2l1 (which encodes the survival factor BCL-X L ) 20 . Bcl2l1-transgenic mice and Stat5b-CA-transgenic mice have a comparable greater number of progenitor B cells than that of their wild-type counterparts 17, 20, 21 . However, overexpression of BCL-X L did not act together with Blnk heterozygosity to initiate leukemia (Fig. 1e) . We then used labeling with the thymidine analog BrdU to determine if STAT5 drives transformation by enhancing cell division. These experiments revealed that Stat5b-CA × Xid leukemia cells did not proliferate significantly more than wild-type or Xid pre-B cells did (Fig. 1f) . Therefore, STAT5 did not induce leukemia solely by promoting survival or enhancing the proliferation of progenitor B cells.
Suppression of STAT5-dependent leukemia by NF-kB
A downstream target of the BLNK-BTK-PKCβ pathway is the transcription factor NF-κB 22 . Microarray analysis established that the expression of 67 of 95 NF-κB target genes normally expressed in pre-B cells was altered in Stat5b-CA × Blnk +/− , Stat5b-CA × Xid and Stat5b-CA × Prkcb −/− leukemia cells relative to that in wild-type pre-B cells ( Fig. 2a and Supplementary Fig. 1b) . The expression of several NF-κB target genes was lower in non-transformed progenitor B cells from Stat5b-CA mice than in wild-type pre-B cells (Fig. 2b) . To further identify genes synergistically regulated by STAT5 and NF-κB, we made use of an algorithm developed to identify factors that act together to regulate downstream target genes 23 . Using this algorithm, we identified 25 NF-κB target genes that were probably synergistically deregulated by activation of STAT5 and decreased pre-BCR signaling, including the oncogenes Bcl2, Ccnd2 and Myc (Fig. 2c) . To determine if STAT5 can deregulate the expression of NF-κB target genes directly, we performed ChIP-Seq analysis of STAT5 in Stat5b-CA × Blnk +/− leukemia cells. STAT5 bound ~30% of all genes and ~50% of NF-κB target genes that were deregulated in all three leukemic strains (Figs. 2d,e and 3a) . One mechanism by which STAT5 might interfere with the expression of NF-κB target genes would be via overlapping DNA-binding sites for STAT5 and NF-κB. Consistent with that idea, binding sites for STAT5 identified by ChIP-Seq analysis of Stat5b-CA × Blnk +/− leukemic cells showed enrichment for nearby binding motifs for NF-κB, relative to the expected frequency in the genome (Fig. 3b, 
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p r e -B A r t i c l e s differentiation (Fig. 3d) . In contrast, when investigating competition at the gene encoding c-Myc (Myc), which regulates the proliferation and growth of pre-B cells, we did not observe such competition and in fact observed enhanced RELA binding (Supplementary Fig. 2a) . Thus, STAT5 competed with NF-κB for binding at some but not all overlapping binding sites.
As an alternative approach for the identification of direct gene targets of STAT5, we used ChIP-BETA software 24 to integrate our STAT5b-CA differential-gene-expression data set from Stat5b-CA × Blnk +/− leukemic cells and wild-type cells (Fig. 2a-c) with our STAT5 ChIP-seq data set (Fig. 2d) . This analysis resulted in the prediction of 4,198 direct regulatory targets of STAT5, including one third of the NF-κB target genes expressed in wild-type pre-B cells ( Supplementary Fig. 2b and data not shown). Thus, STAT5 and NF-κB probably regulate many common target genes. To directly assess whether the interaction between STAT5 and NF-κB1 (encoded by Nfkb1) is important in leukemogenesis, we generated Stat5b-CA × Nfkb1 +/− and Stat5b-CA × Nfkb1 −/− mice; both crosses developed pre-B cell leukemia at a high frequency (Fig. 3e,f) . Together these data suggested that STAT5 and NF-κB affected each other's function at multiple target genes in progenitor B cells and directly demonstrated that NF-κB acted as a tumor suppressor in pre-B cells.
Opposition of IKAROS-dependent gene regulation by STAT5
NF-κB induces expression of the transcription factor IKAROS (encoded by Ikzf1) by upregulating the expression of IRF4 and IRF8 (refs. 25,26) . IKZF1 is frequently deleted in human B-ALL, and such deletion correlates with a poor prognosis [27] [28] [29] . IKAROS-binding motifs showed enrichment near STAT5-binding sites in Stat5b-CA × Blnk +/− leukemia cells, relative to their abundance in the genome (Fig. 3b and Supplementary Table 1) . Furthermore, comparison of our STAT5 ChIP-Seq data set from Stat5b-CA × Blnk +/− leukemic cells with an IKAROS ChIP-Seq A r t i c l e s data set from wild-type pre-B cells 30 showed that 37% of genes bound by IKAROS were also bound by STAT5; 53% of these genes (896) showed direct binding overlap of IKAROS and STAT5 (Fig. 4a-c and Supplementary Fig. 2c) . We found 249 genes that were bound and regulated by IKAROS in wild-type pre-B cells and deregulated in the Stat5b-CA × Blnk +/− , Stat5b-CA × Xid and Stat5b-CA × Prkcb −/− leukemia cells (Fig. 4c) . Of those 249 genes, 180 (72%) showed opposing regulation by STAT5 and IKAROS (Supplementary Table 2 ). Similarly, gene-set-enrichment analysis revealed that the group of genes activated by STAT5 showed enrichment for genes negatively regulated by IKAROS (Fig. 4d) . Thus, STAT5 and IKAROS shared hundreds of target genes, and these transcription factors tended to reciprocally regulate expression of those shared target genes. One way that STAT5 and IKAROS might regulate target-gene expression in an opposing way would be via competition for binding to target loci. To explore this possibility, we used ChIP followed by quantitative PCR (ChIP-qPCR) to analyze the shared target gene Cish (which encodes the JAK-STAT inhibitory protein CIS) in Stat5b-CA × Blnk +/− leukemia cells with and without stimulation by IL-7. Cish was chosen because it is a well-characterized target of STAT5 (ref. 31) and has been shown to be negatively regulated by IKAROS 30 . Treatment with IL-7 led to an increase (of about fourfold) in binding of STAT5 to the Cish promoter and a decrease (of about twofold) in binding of IKAROS to that promoter (Fig. 4e) . To study this in further detail, we cloned the Cish promoter into a luciferase reporter construct. Overexpression of STAT5b-CA induced luciferase activity in the Ba/F3 mouse progenitor B cell line, while co-expression of STAT5b-CA and IKAROS reduced this effect (Fig. 4f) . The repression by IKAROS was alleviated when we mutated the IKAROS-binding sites that overlapped STAT5-binding sites within the Cish promoter (Fig. 4f) . Using a similar luciferase assay approach, we obtained identical results for Socs2 (which encodes the inhibitory protein SOCS2), another gene with overlapping binding sites for STAT5 and IKAROS (Supplementary Fig. 2d) . Thus, STAT5 and IKAROS were able antagonize each other via direct competition for overlapping binding sites.
STAT5 and IKAROS might also regulate shared targets in an opposing way via other mechanisms. One example of this is the Myc locus, which is controlled by a distal super-enhancer located 1.7 Mb downstream of Myc 32 . ChIP-Seq analysis revealed that STAT5 and IKAROS bound at several sites within this Myc super-enhancer (Fig. 5a) . One way that STAT5 activates target-gene transcription is by recruiting the histone acetyltransferase p300 and promoting acetylation of histone H3 at Lys27 (H3K27Ac) 33 . We found that stimulation of IL-7 increased the abundance of STAT5, p300 and H3K27Ac at the Myc super-enhancer in Stat5b-CA × Blnk +/− leukemia cells (about 5-fold, 3-fold and 2.5-fold, respectively) (Fig. 5b) . Similar results were obtained by ectopic expression of STAT5b-CA in Ba/F3 cells: H3K27Ac marks increased 2.2-fold (P < 0.0001 (one-way analysis of variance (ANOVA)) and Myc expression was increased by 38% (Fig. 5c and data not shown). STAT5 regulated the Pim1 locus (which encodes the cytokine-induced kinase Pim-1) and Bcl2l1 locus in a similar manner ( Supplementary Fig. 2e,f) . Stimulation with IL-7 had no effect on the binding of IKAROS at the Myc super-enhancer ( Supplementary  Fig. 2a) , which suggested that STAT5 and IKAROS bound to nonoverlapping sites at this locus. IKAROS can repress gene expression by recruiting the nucleosome-remodeling and deacetylation complex NuRD 34 , which promotes deacetylation of H3K27. Overexpression of Ikzf1 in Ba/F3 cells led to a decrease of about twofold in the active histone mark H3K27Ac at the Myc super-enhancer and a corresponding decrease of twofold in Myc expression (Fig. 5d,e) . Therefore, STAT5 and IKAROS regulated the Myc super-enhancer by regulating histone acetylation in an opposing way.
We next investigated whether constitutively active STAT5 was able to act together with loss-of-function mutations in Ikzf1 to drive B-ALL. The resulting Stat5b-CA × Ikzf1 +/− mice developed leukemia, but only T cell ALL (data not shown). This result was most likely obtained because developing T cells also have high expression of the Stat5b-CA transgene. To circumvent this issue, we used a 'Sleeping Beauty' transposon mutagenesis screen to identify genes that act together with Stat5b-CA to initiate B-ALL. This strategy resulted in highly penetrant B cell leukemia 35 . Notably, Ikzf1 was targeted by the Sleeping Beauty transposon in 15% of the leukemia cells in this screen. The orientation and location of the transposon insertions within the Ikzf1 locus would be predicted to cause loss-of-function mutations; consistent with that prediction, Ikzf1 expression was lower in leukemia cells driven by the Sleeping Beauty transposon than in wild-type pre-B cells 35 . These data provided evidence that activation of STAT5 and loss-of-function mutations in Ikzf1 acted together to initiate both T cell ALL and B-ALL.
Overlapping of STAT5 binding with B cell super-enhancers IKAROS forms a transcriptional network with PAX5, EBF1, PU.1 and IRF4 ('PEPII factors') that regulates B cell differentiation. Binding motifs for PEPII factors showed substantial enrichment near STAT5-binding sites identified in Stat5b-CA × Blnk +/− leukemia cells relative to their abundance throughout the genome (Supplementary Table 1) .
Comparison of ChIP-Seq data sets for PEPII factors 30, [36] [37] [38] and those for STAT5 demonstrated substantial enrichment for PAX5, EBF1, PU.1, IRF4 and IKAROS at STAT5-bound loci (enrichment of 3.8-, 5.3-, 1.9-, 3.1-and 1.7-fold, respectively) relative to their frequency throughout the genome (Fig. 5a,f,g and Supplementary Table 3) . In contrast, the transcription factor FOXO1 did not overlap significantly with STAT5's binding (Fig. 5f) . Thus, the binding of STAT5 directly overlapped binding sites for many but not all transcription factors that promote B cell differentiation.
Studies have identified a class of enhancers, called 'super-enhancers' , that often regulate genes encoding products involved in cell identity and transformation [39] [40] [41] . Consistent with the key role for the PEPII network in B cell development and transformation, 67% of defined super-enhancers in progenitor B cells 39 are bound by four or more members of this network. Notably, 70% of those sites were also bound by STAT5 in leukemia (Fig. 5g) . We next identified enhancers with the greatest content of STAT5 binding by ranking enhancers in progenitor B cells by the amount of STAT5 bound at each enhancer in Stat5b-CA × Blnk +/− leukemia cells. We found that 207 of the 395 previously identified super-enhancers 39 also achieved scores as super-enhancers when the regions were re-assigned scores with the abundance of STAT5 used to define super-enhancer regions (Fig. 5h) . Thus, the binding of STAT5 correlated with super-enhancer identity in progenitor B cells. Notably, the binding of PEPII factors and STAT5 showed enrichment at super-enhancers linked to genes encoding products that regulate survival, the cell cycle and B cell differentiation relative to their binding to other genes (Fig. 5g and Supplementary Table 4) . By ChIP-qPCR, we confirmed that STAT5, PAX5, EBF and IKAROS all bound at the super-enhancers of Myc, Bcl2l1 and Igll1 in the Stat5b-CA × Blnk +/− leukemia cells (Supplementary Fig. 2g) . Moreover, expression of STAT5b-CA led to an increase in H3K27Ac at the superenhancers of Myc and Bcl2l1 (Supplementary Fig. 2f and data not shown), which suggested that STAT5 bound to and promoted the acetylation of multiple super-enhancers in progenitor B cells. Finally, A r t i c l e s genes encoding master transcription factors are themselves driven by super-enhancers in other cell types and form feedback loops in which the key transcription factors regulate their own expression 39 . Consistent with results obtained for other super-enhancer networks, STAT5 and PEPII factors bound to enhancers located within the genes encoding STAT5 and PEPII factors or their functional regulators (i.e., Il7r, Jak1 and Socs3) (Supplementary Fig. 3a,b ) and thus might crossregulate each other. These data demonstrated that STAT5 participated in a regulatory B cell transcriptional network at super-enhancers in progenitor B cells and demonstrated that a high intensity of binding of STAT5 to these super-enhancers was a defining feature of B-ALL.
To determine whether our findings obtained with mouse B-ALL models were recapitulated in human disease, we examined ChIP-Seq data sets for STAT5, NF-κB and IKAROS in a human B lymphoblastoid cell line. We found that 41% or 33% of binding sites for STAT5 in a human B lymphoblastoid cell line overlapped binding sites for IKAROS or NF-κB, respectively (Fig. 6a,b) . In addition, a high intensity of STAT5 binding identified a similar network of super-enhancer-linked genes encoding products associated with survival, proliferation and B cell differentiation (Fig. 6c and Supplementary Table 5) . Moreover, in two primary human BCR-ABL + leukemia samples, we found enrichment for STAT5-binding motifs near IKAROS-binding sites identified by ChIP-Seq, relative to their abundance throughout the genome (Fig. 6d) . Thus, binding of STAT5 overlapped that of NF-κB and IKAROS in transformed human B cells, with a high intensity of STAT5 bound to a similar network of super-enhancers in mouse and human B cell malignancies.
Correlation of STAT5/NF-kB and STAT5/IKAROS ratios with survival
Published studies have linked activation of STAT5 or deletions in IKZF1 to poor patient outcomes 16, 28, 29 . However, the mechanism that accounts for these separate observations, and whether NF-κB is involved, is unclear. To address those questions, we investigated whether the balance of active (phosphorylated) STAT5 (p-STAT5) to IKZF1 correlated with remission duration or overall survival in samples from 64 patients with B-ALL (Supplementary Table 6 ). Patient A r t i c l e s samples were subdivided into three groups: low p-STAT5 and wildtype IKZF1 (two good indicators); low p-STAT5 and deletion of IKZF1 (∆IKZF1), or high p-STAT5 and wild-type IKZF1 (one bad indicator); and high p-STAT5 and deletion of IKZF1 (two bad indicators).
There was a significant decrease in remission duration and patient survival as the number of bad prognostic indicators increased ( Fig. 7a and Supplementary Fig. 4 ). In contrast, the status of p-STAT5 or IKZF1 alone was less effective in prediction of survival or remission duration ( Supplementary Fig. 4 ). One concern with our analysis was that the groups at higher risk showed enrichment for BCR-ABL translocations (data not shown) and this might have accounted for poorer outcomes observed in these groups. However, similar results were obtained when we focused on just one BCR-ABL − subset of B-ALL (B-NOS) and thereby eliminated concerns about inherent differences in survival between different subsets of B-ALL ( Supplementary  Fig. 5) . Thus, the ratio of p-STAT5 to IKAROS was negatively correlated with patient survival and remission duration. We also investigated whether the relationship between p-STAT5 and the NF-κB subunit RELA correlated with survival in 161 patients with B-ALL (Supplementary Table 7) . Patient samples were split into three groups on the basis of total abundance of p-STAT5 and the ratio of p-STAT5 to RELA: low total p-STAT5 and low p-STAT5/RELA (two good indicators); low total p-STAT5 and high p-STAT5/RELA, or high overall p-STAT5 and low p-STAT5/RELA (one bad indicator); and high overall p-STAT5 and high p-STAT5/RELA (two bad indicators). The combination of high p-STAT5 with a high ratio of p-STAT5 to RELA correlated most strongly with decreased survival (Fig. 7b and Supplementary Fig. 6 ). In contrast, the abundance of p-STAT5 or the p-STAT5/RELA ratio alone did not effectively correlate with overall patient survival (Supplementary Fig. 6 ). We obtained similar results after excluding BCR-ABL cases by just focusing on patients with the B-NOS subtype of B-ALL ( Supplementary  Fig. 7) . Moreover, in the samples from patients with B-NOS, we also observed a significant difference for remission duration based on the combination of the abundance of p-STAT5 and the p-STAT5/RELA ratio and that based on the p-STAT5/RELA ratio alone (P = 0.0277 (log-rank test for trend of medians); Supplementary Fig. 7) . Thus, the ratio of p-STAT5 to RELA correlated with patient outcome. In summary, our studies suggested that the degree of imbalance between STAT5 and a transcription-factor network, including IKAROS and NF-κB, governed the likelihood of survival for patients with B-ALL (Supplementary Fig. 8 ).
DISCUSSION
Our studies of B-ALL have identified a linear tumor-suppressor pathway downstream of the pre-BCR involving BLNK, BTK, PKCβ, NF-κB1 and IKAROS. These findings were particularly intriguing because members of the NF-κB family were initially identified as oncoproteins, not tumor suppressors, in other cancers 42 . Constitutively active NF-κB has been reported in some B cell malignancies 43, 44 . In contrast, we demonstrated that for progenitor B cell leukemia, NF-κB1 acted functionally as a tumor suppressor. Consistent with that observation, we observed that the ratio of p-STAT5 to the NF-κB family member RELA in human progenitor B cell leukemia correlated with patient survival and disease remission. In part, this observation reflected direct competition between STAT5 and NF-κB for common binding sites. However, competition between STAT5 and NF-κB was not observed at all overlapping binding sites for STAT5 and NF-κB. Specifically, we observed clear antagonism at the Igk locus, which encodes a product involved in the differentiation of pre-B cells, but observed enhanced binding at the super-enhancer of Myc, which encodes a product involved in the proliferation and growth of pre-B cells. While our findings for Igk and Myc were obtained with a limited sample size, they might be indicative of a broader phenomenon. STAT5 might antagonize the binding of NF-κB at NF-κB's target genes encoding products involved in B cell differentiation, while STAT5 might enhance the binding of NF-κB at genes encoding products involved in proliferation. In this model, reduced expression of NF-κB would allow more-effective STAT5-dependent inhibition of pre-B cell differentiation. In parallel, activation of STAT5 would compensate for the effects of less NF-κB on NF-κB's gene targets encoding products involved in cell proliferation. Our studies also demonstrated a much broader role for STAT5 in B cell development and transformation than previously suspected. Published studies have demonstrated that STAT5 provides important survival signals to progenitor B cells 11, 12 . In addition, STAT5 regulates many genes encoding products involved in cell growth and proliferation, including Ccnd2, Ccnd3 and Myc. However, beyond regulating genes encoding products that promote survival and proliferation, STAT5 also bound to a large subset of genes encoding products that regulate the normal development of progenitor B cells, These include genes encoding components of the pre-BCR pathway, including the pre-BCR (λ5 and VpreB1), the associated signaling immunoglobulin α-chain, the upstream kinases SYK and BLK, the adaptors BLNK and CARMA1 (which has a key role in activating NF-κB downstream of the pre-BCR), and the downstream transcription factors IRF4, IRF8, IKAROS and AIOLOS. These results suggest that STAT5 not only has a key role during the transformation of progenitor B cells but probably also has an important role during the normal development of B cells to ensure sufficient population expansion of progenitor B cells and to prevent premature B cell differentiation.
In addition to interactions with NF-κB, we found substantial overlap in the binding of STAT5 to previously identified IKAROS-binding sites in pre-B cells. In the majority of cases (72%), these involved genes that were regulated in one direction by IKAROS and in the opposite direction in our STAT5b-CA-driven leukemia. We provided evidence for at least two mechanisms that could explain these results. First, STAT5 and IKAROS directly competed for overlapping binding sites at some target genes. Second, at other sites, such as the Myc super-enhancer, STAT5 increased the abundance of H3K27ac and expression of Myc. In contrast, the binding of IKAROS appeared to reverse the abundance of H3K27ac at the Myc locus and repressed Myc expression. These results were consistent with a published report showing that that histone deacetylases reverse both the STAT5-dependent recruitment of the bromodomain protein BRD2 to the Myc super-enhancer and STAT5-dependent Myc transcription 45 . Thus, competition between STAT5-dependent histone acetylation and IKAROS-dependent histone deacetylation of the Myc super-enhancer probably has an important role in pre-B cell transformation. Other mechanisms could be involved as well. For example, STAT5 bound to genes encoding PAX5, EBF1, PU.1, IRF4 and IKAROS (PEPII factors). Likewise, these PEPII factors bound to genes encoding products involved in the STAT5 signaling pathways, including Il7r, Jak1, Stat5b and Socs3. This suggested that STAT5 and the PEPII factors might cross-regulate each other and thus form another level of regulation.
The interaction between STAT5 and IKAROS has important functional consequences for patients with B-ALL. Consistent with published studies 16, 28, 29 , we found that both the phosphorylation of STAT5 and IKZF1-deletion status correlated with patient survival and remission duration (hazard ratio for overall survival: 2.2-fold and 2.5-fold, respectively). In contrast, splitting patients into distinct hazard groups on the basis of both IKZF1-deletion status and activation (phosphorylation) of STAT5 correlated much more strongly with patient survival (hazard ratio: 20-fold for overall survival).
Qualitatively similar results were obtained in a comparison of the ratio of p-STAT5 to RELA, although the magnitude of the difference was smaller. This might have been due to the fact that multiple members of the NF-κB family, including c-REL and NF-κB1, are involved in pre-BCR signaling and that the strongest predictive power is achieved only when all relevant members of the NF-κB family are considered. This might also explain why Stat5b-CA × Nfkb1 +/− leukemia was not as penetrant as Stat5b-CA × Blnk +/− leukemia. Another explanation could be that N-FκB might have both tumor-suppressor roles and oncogenic roles in progenitor B cells via its regulation of B cell differentiation and B cell proliferation, respectively. Notably, the magnitude of the imbalance between the STAT5 pathway and NF-κB-IKAROS pathway correlated powerfully with disease outcome. Thus, future work taking this observation into account should allow the development of clinical tests that better stratify patients into high-and low-risk groups.
In summary, our studies suggest a model in which the balance between STAT5 and a specific transcription-factor network at superenhancers acts as a molecular switch to govern the appropriate proliferation, survival and differentiation of progenitor B cells. Altering the balance between these two antagonistic pathways drives B cell transformation, while the degree of imbalance underlies how patients with B-ALL will respond to therapy. Our findings suggest that strategies aimed at modestly altering this balance, involving submaximal inhibition of STAT5 paired with modest agonism of NF-κB or induction of IKAROS could effectively inhibit B-ALL with minimal effects on other processes dependent on STAT5 and NF-κB-IKAROS.
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